Nipocalimab Benefits Mechanism of HDFN in Phase 2 Trial

Janssen reported significant benefit, and a tolerable profile, for the investigative drug that may become the first indicated to treat HDFN.

Related Keywords

Valencia ,Carabobo ,Venezuela ,Katie Abouzahr ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,European Medicines Agency ,Twitter ,Janssen Research Development ,Fetal Medicine Foundation World Congress ,Pharmaceutical Companies ,Janssen Research ,Fast Track ,